[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-cancer-associated-with-cystic-airspaces\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-cancer-associated-with-cystic-airspaces":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,37],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100598078","staging-strategies-and-their-association-with-prognosis-and-therapy-in-lung-cancer-with-cystic-airspaces-100598078",false,"NCT07066813","Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces","T-Staging Strategies and Their Prognostic and Therapeutic Significance in Lung Cancer With Cystic Airspaces: A Retrospective Cohort Study","Inclusion Criteria:\n\n1. Histologically confirmed non-small cell lung cancer (NSCLC), as verified by biopsy or postoperative pathological examination;\n2. Patients who have undergone surgical lung resection;\n3. Patients with complete preoperative chest CT imaging data;\n4. Preoperative chest CT showing a well-defined gas-containing (air-filled) cystic component within the tumor.\n\nExclusion Criteria:\n\n1. History of pulmonary diseases that could produce cystic lung lesions (e.g., tuberculosis, pulmonary fungal infections, bullae, emphysema, Lymphangioleiomyomatosis \\[LAM\\], or Birt-Hogg-Dubé \\[BHD\\] syndrome);\n2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;\n3. Patients with concurrent other malignancies;\n4. Patients with missing or poor-quality preoperative chest CT imaging data.","ALL",{"count":18,"type":19},500,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to determine the most accurate tumor size measurement method for T-staging and prognostic assessment in lung cancer with cystic airspaces (LCCA). The main questions it aims to answer are:\n\n* What is the optimal T-staging approach for accurately classifying lung cancer with cystic airspaces （LCCA) and predicting patient outcomes?\n* How do imaging features of cystic lesions correlate with their pathological characteristics?\n* What is the relationship between imaging features of cystic airspace-associated lesions and patient prognosis?\n* Can optimizing the T-staging method improve clinical decision-making in patients with LCCA?",[23],"Lung Cancer Associated With Cystic Airspaces","RECRUITING","2026-03-16",{"date":27,"type":28},"2026-03-18","ACTUAL",{"date":30,"type":28},"2025-06-01",{"date":32,"type":19},"2026-07-01",{"name":34,"class":35},"Central South University","OTHER",1,{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":16,"minAge":44,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":47,"conditions":48,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":51,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":36},"100569879","multi-omics-study-of-early-stage-lung-cancer-with-distinct-phenotypes-100569879","NCT06699979","Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes","Comprehensive Multi-Omics Analysis of Early-Stage Lung Cancer Exhibiting Distinct Phenotypes","Cohort 1: Multi-omics study in early-stage synchronous multiple primary lung cancer\n\nInclusion criteria:\n\n1. Male or female patients:18-75 years old;\n2. ECOG score:0-1;\n3. Histopathologically confirmed TNM stage I-II NSCLC;\n4. Considered multiple or solitary primary lung cancer by clinical criteria (Martini-Melamed criteria and ACCP criteria);\n5. Good compliance, family members agree to cooperate to receive survival follow-up;\n6. Understand and voluntarily sign the informed consent.\n\nExclusion criteria:\n\n1. A history of previous or co-existing malignant tumors;\n2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;\n3. Refusal to participate in the study.\n\nCohort 2: Multi-omics study of lung cancer associated with cystic airspaces\n\nInclusion criteria:\n\n1. Male or female patients:18-75 years old;\n2. ECOG score:0-1;\n3. Histopathologically confirmed TNM stage I-II NSCLC;\n4. CT findings show solitary or multiple nodules with cystic airspaces.\n\nExclusion criteria:\n\n1. A history of previous or co-existing malignant tumors;\n2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment;\n3. Refusal to participate in the study.","18 Years",{"count":46,"type":19},300,"The goal of this observational study is to investigate the multi-omics characterization early-stage lung cancer exhibiting distinct phenotypes including lung cancer associated with cystic airspaces, multiple primary lung cancers, and so on. The main questions it aims to answer are:\n\n* What are the differences in pathogenesis of non-small cell lung cancer with different phenotypes explored by multi-omics?\n* Whether differential genes lead to potential prognostic models and therapeutic targets? Participants will be followed up after surgery to answer prognosis: whether they have recurred, and the time to recurrence.",[23,49,50],"Multiple Primary Lung Cancers","Non-Small Cell Lung Cancer",{"date":27,"type":28},{"date":53,"type":28},"2024-08-29",{"date":55,"type":19},"2027-12-31",{"name":34,"class":35}]